It's been a busy year for Swift Biosciences. The Ann Arbor-based life sciences firm has launched its first product, readied a handful of new products to hit the market within the next 12 months and nearly doubled its staff.
now employs 11 people after adding five in the last year, and plans to hire another four more soon. Most of those jobs are in research & development with a sprinkling of sales and marketing. Of the five most recently hired, Swift Biosciences was able to recruit three from out of state.
"The quality of life here in Ann Arbor is a significant feature for us," says David Olson
, CEO of Swift Biosciences
The 2-year-old start-up is developing molecular biology reagents for research and diagnostic applications that provide new ways to examine disease-related genes. This technology is expected to help researchers analyze samples faster, at a higher volume, and at a lower price-per-sample. It's first piece of technology, launched early this year, is a consumable product for genetic analysis that helps detect mutations in things like cancer with high sensitivity.
The venture-backed start-up, Houston-based DFJ Mercury has led its latest round of fundraising, is also working to release 2-3 more products over the next 12 months. Those include some variations of its current platform and new technology.
"It's focused on genetic sequencing," Olson says. "It's in the same general space as our first product."
Source: David Olson, CEO of Swift Biosciences
Writer: Jon Zemke